New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
07:34 EDTPOZNPOZEN presents PA32540 Phase 3 data
POZEN presented data from the combined results of two Phase 3 studies of PA32540, an antiplatelet therapy of enteric-coated and immediate-release omeprazole, in patients with previous cerebrovascular disease. These data were presented at the American Heart Association 2013 International Stroke Conference. According to the studies, in the post-hoc analysis of subjects with a history of transient ischemic attack or stroke, long-term treatment with PA32540, compared to EC-ASA, was associated with a significantly reduced rate of endoscopic gastroduodenal ulcers, and study discontinuation due to adverse pre-specified upper GI events. The incidence of adjudicated major adverse cardiac events was similar for PA32540 and EC-ASA. Key Findings of the Study: PA32540 is associated with a lower rate of endoscopic gastroduodenal mucosal injury with a similar cerebrovascular event profile as EC-ASA therapy; PA32540, a single tablet containing EC aspirin and IR omeprazole, has a lower rate of discontinuation and, hence, may improve long-term adherence to ASA therapy.
News For POZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 5, 2016
13:20 EDTPOZNPOZEN, Tribute complete combination to create Aralez Pharmaceuticals
Subscribe for More Information
February 2, 2016
09:04 EDTPOZNPOZEN's stockholders approved merger with Tribute Pharma Canada
POZEN announced that its stockholders approved the Agreement and Plan of Merger and Arrangement with Tribute Pharmaceuticals Canada and the carrying out of the transactions contained therein. Upon closing of the transaction, the POZEN and Tribute businesses will operate as subsidiaries of Aralez Pharmaceuticals, a company domiciled in Canada. The Merger Agreement was also adopted by the Tribute shareholders on February 1. The proposed transaction remains subject to certain conditions and approvals, including approval of the Ontario Superior Court of Justice, listing of Aralez shares and customary closing conditions, and is expected to occur promptly following satisfaction of all conditions. Aralez will be listed on the NASDAQ stock exchange under the ticker symbol "ARLZ" and is expected to begin trading on or about February 8 and will be listed on the Toronto Stock Exchange under the ticker symbol "ARZ" and is expected to begin trading on on or about February 10, assuming closing on February 5.
February 1, 2016
14:49 EDTPOZNPOZEN to host special shareholder meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use